AHCO

AdaptHealth Corp. Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers AdaptHealth Corp.'s (AHCO) Form 10-Q for the quarterly period ended March 31, 2026. AdaptHealth is a national provider of home medical equipment (HME), supplies, and services, operating through four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. The company services approximately 4.5 million patients annually across 670 locations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 5.4% year-over-year, driven by a 9.1% increase in organic revenue. Growth was led by Sleep Health (+13.3%) and Respiratory Health (+7.6%) segments, primarily due to new at-risk capitated contracts entered in late 2025. Wellness at Home revenue declined 10.3% due to prior-year dispositions of incontinence and infusion businesses.
• Profitability Pressure: Operating income fell 76.3% to $5.5 million. While revenue grew, costs increased faster, particularly labor costs (+15.8%) and patient equipment depreciation (+14.8%) to support new capitated contracts. Adjusted EBITDA decreased 5.3% to $121.2 million.
• Cash Flow Dynamics: Operating cash flow remained robust at $93.7 million. However, Free Cash Flow turned significantly negative at $(27.5) million due to $121.2 million in capital expenditures for patient equipment and $84.7 million in acquisition-related cash outflows.
• Debt Refinancing: Subsequent to the quarter end (April 10, 2026), the company refinanced its credit facility, entering a new 2026 Credit Agreement with a $325 million term loan, $325 million delayed draw term loan, and $450 million revolver.

Guidance, Outlook, and Risks

• Management Commentary: Management attributes the decline in Adjusted EBITDA margin to higher costs associated with ramping up new capitated contracts and inflationary pressures on labor and supplies. The company expects these investments to drive future growth.
• Legal Contingencies: The company reached an agreement in principle to settle the Allegheny County Consolidated Class Action for $35 million ($34 million funded by insurance, $1 million by the company). The $1 million portion was paid in Q1 2026. Several shareholder derivative actions remain pending but have reached settlement agreements in principle.
• Regulatory Risks: In February 2026, the Centers for Medicare & Medicaid Services (CMS) imposed a 6-month nationwide temporary moratorium on Medicare enrollment for certain DMEPOS supplier types. This could limit the company's ability to open new locations or consummate acquisitions requiring new enrollments.
• Outlook: The company maintains that its operating cash flows and credit facilities are sufficient to fund operations for the next 12 months. No specific forward-looking financial guidance was provided in this filing.

Investor Verification Checklist

• Capitated Contract Margins: Verify the timeline for profitability on the new at-risk capitated contracts driving revenue growth in Sleep and Respiratory segments, given the current drag on Adjusted EBITDA.
• Debt Covenant Compliance: Confirm compliance with the new 2026 Credit Agreement covenants (Consolidated Total Leverage Ratio and Interest Coverage Ratio) following the April 2026 refinancing.
• Legal Settlement Finalization: Monitor the final court approval of the $35 million Allegheny County settlement and the status of the derivative actions (Wu, Frankel, Myers) to ensure no additional unexpected liabilities arise.
• CMS Moratorium Impact: Assess the operational impact of the CMS enrollment moratorium on planned expansion and acquisition strategies for the remainder of 2026.
• Free Cash Flow Recovery: Track the trajectory of capital expenditures to determine when Free Cash Flow will return to positive territory after the heavy investment in patient equipment.